4.40
+0.41(+10.28%)
Currency In USD
Address
300 East Main Street
Charlottesville, VA 22902
United States of America
Phone
434 220 0718
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
May 23, 2008
| Name | Title | Pay | Year Born |
| Dr. Robert J. Cobuzzi Jr., Ph.D. | Pres & Chief Executive Officer | 691,787 | 1965 |
| Mr. William Robert Elder J.D. | Gen. Counsel & Corporation Sec. | 413,923 | 1983 |
| Mr. William Karl Hornung | Chief Financial Officer | 460,126 | 1969 |
| Dr. Christopher D. Galloway M.D. | Chief Medical Officer | 539,592 | 1972 |
| Ms. Kelly Hoy | Director of Project Management | 0 | N/A |
| Ms. Suzanne Cassidy | Senior Director & Head of Quality Assurance | 0 | N/A |
| Dr. Jennifer Llewelyn Ph.D. | Senior Director & Head of CMC | 0 | N/A |
| Dr. David Randolph Jones M.D. | Senior Medical Advisor | 0 | 1963 |
| Mr. Harry Cook | Vice President of Clinical Operations | 0 | N/A |
| Mr. Douglas Gravatt | Senior Consultant for Manufacturing | 0 | N/A |
| Mr. Brian D. Bollwage | Senior Consultant - Regulatory Affairs | 0 | N/A |
| Ms. Raven Jaeger M.S. | Chief Regulatory Officer | 0 | 1978 |
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.